The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jodo, S.
Right arrow Articles by Ju, S.-T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jodo, S.
Right arrow Articles by Ju, S.-T.
The Journal of Immunology, 2000, 164: 5062-5069.
Copyright © 2000 by The American Association of Immunologists

Bioactivities of Fas Ligand-Expressing Retroviral Particles1

Satoshi Jodo, David Strehlow and Shyr-Te Ju2

Arthritis Center, Department of Medicine, Boston University School of Medicine, Boston, MA 02118

Culture supernatants from retroviral packaging cells carrying the human Fas ligand (FasL) gene killed both human (Jurkat) and mouse (LB27.4) targets within 5 h of incubation. Cytotoxicity was found both in a fraction >=500 kDa and a fraction between 50 and 500 kDa. Following ultracentrifugation, the activity in the >=500-kDa fraction was concentrated in the pellet (FasL vector preparation (VP)), which was also infective when added to NIH-3T3 cells. Both Polybrene and poly-L-lysine significantly enhanced the cytotoxicity of FasL VP but not anti-Fas mAb, soluble FasL (sFasL), and cell-associated FasL. In the presence of Polybrene, FasL VP killed targets that are resistant to anti-Fas mAb and sFasL. The infectivity but not FasL cytotoxicity of FasL VP was sensitive to irradiation and heat shock. By contrast, cytotoxicity of FasL VP could be enhanced or inhibited depending on the doses of anti-FasL mAb. Interestingly, the infectivity of FasL VP was specifically enhanced by anti-FasL mAb, suggesting that a nonviral gene product could be used to regulate the behavior of the retroviral vector. Thus, in addition to expressing potent FasL cytotoxicity, the FasL VP exhibits unique properties heretofore not attributed to anti-Fas mAb, sFasL, and cell-associated FasL. Our study raises the possibility of using the retroviral gene-packaging technology to make powerful, versatile, and regulatable bioactive vesicles expressing a predetermined function of the protein encoded by the target gene.




This article has been cited by other articles:


Home page
J. Leukoc. Biol.Home page
N. Engedal, P. Auberger, and H. K. Blomhoff
Retinoic acid regulates Fas-induced apoptosis in Jurkat T cells: reversal of mitogen-mediated repression of Fas DISC assembly
J. Leukoc. Biol., March 1, 2009; 85(3): 469 - 480.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Chahlavi, P. Rayman, A. L. Richmond, K. Biswas, R. Zhang, M. Vogelbaum, C. Tannenbaum, G. Barnett, and J. H. Finke
Glioblastomas Induce T-Lymphocyte Death by Two Distinct Pathways Involving Gangliosides and CD70
Cancer Res., June 15, 2005; 65(12): 5428 - 5438.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
S. Xiao, X. Zhang, K. K. Mann, S. Jodo, L. Li, W. N. Jarjour, A. Marshak-Rothstein, D. H. Sherr, and S.-T. Ju
Changes in sensitivity of peripheral lymphocytes of autoimmune gld mice to FasL-mediated apoptosis reveal a mechanism for the preferential deletion of CD4-CD8-B220+ T cells
Int. Immunol., May 1, 2004; 16(5): 759 - 766.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
S. J. Gould, A. M. Booth, and J. E. K. Hildreth
The Trojan exosome hypothesis
PNAS, September 16, 2003; 100(19): 10592 - 10597.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Xiao, S. Jodo, S.-s. J. Sung, A. Marshak-Rothstein, and S.-T. Ju
A Novel Signaling Mechanism for Soluble CD95 Ligand. SYNERGY WITH ANTI-CD95 MONOCLONAL ANTIBODIES FOR APOPTOSIS AND NF-kappa B NUCLEAR TRANSLOCATION
J. Biol. Chem., December 20, 2002; 277(52): 50907 - 50913.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
I. Monleon, M. J. Martinez-Lorenzo, L. Monteagudo, P. Lasierra, M. Taules, M. Iturralde, A. Pineiro, L. Larrad, M. A. Alava, J. Naval, et al.
Differential Secretion of Fas Ligand- or APO2 Ligand/TNF-Related Apoptosis-Inducing Ligand-Carrying Microvesicles During Activation-Induced Death of Human T Cells
J. Immunol., December 15, 2001; 167(12): 6736 - 6744.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Jodo, S. Xiao, A. Hohlbaum, D. Strehlow, A. Marshak-Rothstein, and S.-T. Ju
Apoptosis-inducing Membrane Vesicles. A NOVEL AGENT WITH UNIQUE PROPERTIES
J. Biol. Chem., October 19, 2001; 276(43): 39938 - 39944.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Jodo, A. M. Hohlbaum, S. Xiao, D. Chan, D. Strehlow, D. H. Sherr, A. Marshak-Rothstein, and S.-T. Ju
CD95 (Fas) Ligand-Expressing Vesicles Display Antibody-Mediated, FcR-Dependent Enhancement of Cytotoxicity
J. Immunol., November 15, 2000; 165(10): 5487 - 5494.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2000 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2000 by The American Association of Immunologists, Inc. All rights reserved.